139 related articles for article (PubMed ID: 34935059)
1. Berberine enhances gemcitabine‑induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway.
Gao X; Liu J; Fan D; Li X; Fang Z; Yan K; Fan Y
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34935059
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells.
Tsai MS; Kuo YH; Chiu YF; Su YC; Lin YW
J Pharmacol Exp Ther; 2010 Dec; 335(3):830-40. PubMed ID: 20855443
[TBL] [Abstract][Full Text] [Related]
3. Low‑intensity low‑frequency ultrasound enhances the chemosensitivity of gemcitabine‑resistant ASPC‑1 cells via PI3K/AKT/NF‑κB pathway‑mediated ABC transporters.
Qiu F; Chen J; Cao J; Diao F; Huang P
Oncol Rep; 2020 Sep; 44(3):1158-1168. PubMed ID: 32705228
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumour effects of triptolide plus gemcitabine in bladder cancer.
Yang Y; Zhang LJ; Bai XG; Xu HJ; Jin ZL; Ding M
Biomed Pharmacother; 2018 Oct; 106():1307-1316. PubMed ID: 30119201
[TBL] [Abstract][Full Text] [Related]
5. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.
Ko JC; Ciou SC; Jhan JY; Cheng CM; Su YJ; Chuang SM; Lin ST; Chang CC; Lin YW
Mol Cancer Res; 2009 Aug; 7(8):1378-89. PubMed ID: 19671683
[TBL] [Abstract][Full Text] [Related]
6. lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway.
Sun ZY; Jian YK; Zhu HY; Li B
Pathol Res Pract; 2019 Mar; 215(3):555-563. PubMed ID: 30661902
[TBL] [Abstract][Full Text] [Related]
7. Tectoridin inhibits the growth of bladder cancer by regulating PI3K/MAPK pathway through RAB27B.
Zhang Q; Wang L; Yu L; Yu Q; Xue L; Shen Z
Mol Carcinog; 2024 Jun; 63(6):1106-1116. PubMed ID: 38441297
[TBL] [Abstract][Full Text] [Related]
8. Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
Wu ZH; Lin C; Liu MM; Zhang J; Tao ZH; Hu XC
PLoS One; 2016; 11(12):e0169230. PubMed ID: 28036386
[TBL] [Abstract][Full Text] [Related]
9. Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cells.
Ko JC; Chen JC; Wang TJ; Zheng HY; Chen WC; Chang PY; Lin YW
Biochem Pharmacol; 2016 Apr; 105():91-100. PubMed ID: 26921637
[TBL] [Abstract][Full Text] [Related]
10. Activation of a c-Jun N-terminal kinase-mediated autophagy pathway attenuates the anticancer activity of gemcitabine in human bladder cancer cells.
Huang XL; Zhang H; Yang XY; Dong XY; Xie XY; Yin HB; Gou X; Lin Y; He WY
Anticancer Drugs; 2017 Jul; 28(6):596-602. PubMed ID: 28430744
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway.
Zhou HY; Yao XM; Chen XD; Tang JM; Qiao ZG; Wu XY
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10283-10289. PubMed ID: 31841183
[TBL] [Abstract][Full Text] [Related]
12. Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells.
Jeon HG; Yoon CY; Yu JH; Park MJ; Lee JE; Jeong SJ; Hong SK; Byun SS; Lee SE
J Urol; 2011 Nov; 186(5):2084-93. PubMed ID: 21944112
[TBL] [Abstract][Full Text] [Related]
13. LncRNA AB209630 inhibits gemcitabine resistance cell proliferation by regulating PI3K/AKT signaling in pancreatic ductal adenocarcinoma.
Wang L; Wang F; Na L; Yu J; Huang L; Meng ZQ; Chen Z; Chen H; Ming LL; Hua YQ
Cancer Biomark; 2018; 22(1):169-174. PubMed ID: 29526843
[TBL] [Abstract][Full Text] [Related]
14. Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth.
Pal J; Fulciniti M; Nanjappa P; Buon L; Tai YT; Tassone P; Munshi NC; Shammas MA
Cancer Genomics Proteomics; 2012; 9(2):55-66. PubMed ID: 22399496
[TBL] [Abstract][Full Text] [Related]
15. Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in bladder cancer cells.
Takeuchi H; Mmeje CO; Jinesh GG; Taoka R; Kamat AM
Oncol Rep; 2015 Nov; 34(5):2738-44. PubMed ID: 26323344
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer.
Li B; Xie D; Zhang H
Cancer Chemother Pharmacol; 2019 Jul; 84(1):187-194. PubMed ID: 31115606
[TBL] [Abstract][Full Text] [Related]
17. Irisin Enhances Doxorubicin-Induced Cell Apoptosis in Pancreatic Cancer by Inhibiting the PI3K/AKT/NF-κB Pathway.
Liu J; Huang Y; Liu Y; Chen Y
Med Sci Monit; 2019 Aug; 25():6085-6096. PubMed ID: 31412018
[TBL] [Abstract][Full Text] [Related]
18. Coptisine-induced apoptosis in human colon cancer cells (HCT-116) is mediated by PI3K/Akt and mitochondrial-associated apoptotic pathway.
Han B; Jiang P; Li Z; Yu Y; Huang T; Ye X; Li X
Phytomedicine; 2018 Sep; 48():152-160. PubMed ID: 30195873
[TBL] [Abstract][Full Text] [Related]
19. Berberine could inhibit thyroid carcinoma cells by inducing mitochondrial apoptosis, G0/G1 cell cycle arrest and suppressing migration via PI3K-AKT and MAPK signaling pathways.
Li L; Wang X; Sharvan R; Gao J; Qu S
Biomed Pharmacother; 2017 Nov; 95():1225-1231. PubMed ID: 28931215
[TBL] [Abstract][Full Text] [Related]
20. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
Mey V; Giovannetti E; De Braud F; Nannizzi S; Curigliano G; Verweij F; De Cobelli O; Pece S; Del Tacca M; Danesi R
Br J Cancer; 2006 Aug; 95(3):289-97. PubMed ID: 16868547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]